Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the Noble Financial Capital Markets 11th Annual Investor Conference. The presentation will take place on Tuesday, January 20, 2015 at 2:00 p.m. ET in Sandpiper Bay, Florida… Read more »
Shares of Galena Biopharma closed yesterday at $1.86 . GALE has a 1-year high of $7.48 and a 1-year low of $1.43. The stock’s 50-day moving average is $1.63 and it’s 200-day moving average is $2.16.
On the ratings front, Galena Biopharma has been the subject of a number of recent research reports. In a report published on January 8, analyst Joseph Pantginis from Roth Capital reiterated a Buy rating on GALE, with a price target of $8, which implies an upside of 330.1% from current levels. Separately, on November 20, MLV & Co.`s Vernon Bernardino reiterated a Buy rating on Galena Biopharma shares and has a price target of $5.
In total, one research analyst has assigned a Hold rating and 3 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $1.86 which is 249.5% above where the stock closed yesterday.
Galena Biopharma Inc, is a biopharmaceutical company focused on developing and commercializing, targeted treatments that address unmet medical needs to advance cancer care.